The prognostic value of RS had been validated in hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative, 0–3 lymph node-involved breast cancer patients [4]. This evidence concerns the gene ERBB2 and breast carcinoma.